- Home
- ONCT vs ICON Comparison
ONCT vs ICON Comparison
Compare ONCT & ICON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCT
- ICON
- Stock Information
- Founded
- ONCT N/A
- ICON 2023
- Country
- ONCT United States
- ICON Greece
- Employees
- ONCT N/A
- ICON N/A
- Industry
- ONCT Biotechnology: Pharmaceutical Preparations
- ICON
- Sector
- ONCT Health Care
- ICON
- Exchange
- ONCT Nasdaq
- ICON Nasdaq
- Market Cap
- ONCT 4.3M
- ICON 3.6M
- IPO Year
- ONCT N/A
- ICON 2024
- Fundamental
- Price
- ONCT $1.13
- ICON $2.14
- Analyst Decision
- ONCT Buy
- ICON Strong Buy
- Analyst Count
- ONCT 3
- ICON 1
- Target Price
- ONCT $10.00
- ICON $7.00
- AVG Volume (30 Days)
- ONCT 156.9K
- ICON 12.2K
- Earning Date
- ONCT 11-06-2024
- ICON 11-26-2024
- Dividend Yield
- ONCT N/A
- ICON 3.74%
- EPS Growth
- ONCT N/A
- ICON N/A
- EPS
- ONCT N/A
- ICON 0.34
- Revenue
- ONCT $2,161,000.00
- ICON $4,810,000.00
- Revenue This Year
- ONCT $113.76
- ICON $64.08
- Revenue Next Year
- ONCT N/A
- ICON $100.00
- P/E Ratio
- ONCT N/A
- ICON $6.25
- Revenue Growth
- ONCT 227.92
- ICON N/A
- 52 Week Low
- ONCT $1.03
- ICON $1.81
- 52 Week High
- ONCT $13.20
- ICON $3.85
- Technical
- Relative Strength Index (RSI)
- ONCT 37.09
- ICON N/A
- Support Level
- ONCT $1.03
- ICON N/A
- Resistance Level
- ONCT $1.30
- ICON N/A
- Average True Range (ATR)
- ONCT 0.19
- ICON 0.00
- MACD
- ONCT -0.01
- ICON 0.00
- Stochastic Oscillator
- ONCT 13.70
- ICON 0.00
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.